雷帕霉素靶蛋白信号通路与靶向雷帕霉素靶蛋白抗肿瘤药物研究进展  

Progress in mTOR pathway and mTOR targeted anticancer drugs

作　　者：林辰初[1] 袁胜涛[1] 

机构地区：[1]中国药科大学新药筛选中心,南京210009

出　　处：《中国新药杂志》2013年第14期1656-1666,共11页Chinese Journal of New Drugs

摘　　要：磷脂肌醇3-激酶(PI3K)-雷帕霉素靶蛋白(mTOR)信号通路是受生长因子调控的最重要的信号转导途径之一。PI3K/mTOR通路能响应多种环境刺激,直接或间接参与细胞增殖、生长和代谢等多个关键事件的调控。PI3K/mTOR通路在多种肿瘤中异常激活,在肿瘤发生、发展及转移中发挥重要作用。mTOR激酶处于该信号转导通路的中枢,抑制mTOR是靶向PI3K/mTOR通路的重要策略,mTOR抑制剂的研发已成为抗肿瘤研究的前沿和热点领域。本文就mTOR信号转导通路在肿瘤发生发展中的作用以及mTOR抑制剂的研究进展进行综述。PI3K/mTOR signaling pathway is one of the most vital transduction processes controlled by growth factors.This pathway responds to diverse environmental cues to directly or / and indirectly regulate cellular processes involving proliferation,growth and metabolism.PI3K / mTOR signaling is overactivated in various cancers and plays an important role in cancer development,progression and metastasis.Targeting mTOR allows the effective intervention of PI3K / mTOR signaling and has been proven as an important anticancer strategy.Development of mTOR inhibitors represents a promising field in anticancer research.This review provides an updated summary in the mechanistic insights into mTOR signaling pathway and the current status of the development of mTOR inhibitors.

关 键 词：雷帕霉素靶蛋白 雷帕霉素靶蛋白抑制剂 肿瘤 

分 类 号：R979.1[医药卫生—药品]